Selux Diagnostics is developing a Next-Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital-acquired infections, and help combat the global antibiotic resistance epidemic. 

Biotechnology

Selux Diagnostics

Selux Diagnostics' headquarters in Boston, MA, United States

People (9)

Jobs (1)

Other offices